GNRO.PA Stock - GeNeuro S.A.
Unlock GoAI Insights for GNRO.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-293,800 | $-288,500 | $-300,200 | $-334,600 | $-354,800 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-14,357,300 | $-13,055,000 | $-7,539,200 | $-8,040,500 | $-9,918,800 |
| Net Income | $-14,757,000 | $-12,199,800 | $-6,817,700 | $-8,962,300 | $-9,460,800 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.59 | $-0.51 | $-0.32 | $-0.45 | $-0.65 |
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Visit WebsiteEarnings History & Surprises
GNRO.PAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Jun 6, 2025 | — | — | — | — |
Q2 2025 | May 30, 2025 | — | — | — | — |
Q4 2024 | Nov 18, 2024 | — | — | — | — |
Q2 2024 | Apr 30, 2024 | — | $-0.00 | — | — |
Q3 2023 | Jul 25, 2023 | — | $-0.28 | — | — |
Q2 2023 | Apr 5, 2023 | — | $-0.26 | — | — |
Q4 2022 | Oct 24, 2022 | — | $-0.25 | — | — |
Q2 2022 | Apr 15, 2022 | — | $-0.15 | — | — |
Q3 2021 | Sep 22, 2021 | — | $-0.17 | — | — |
Q2 2021 | Apr 10, 2021 | — | $-0.25 | — | — |
Q4 2020 | Nov 17, 2020 | — | $-0.20 | — | — |
Q2 2020 | Apr 7, 2020 | — | $-0.34 | — | — |
Q4 2019 | Oct 25, 2019 | — | $-0.31 | — | — |
Q2 2019 | Apr 1, 2019 | — | $-0.41 | — | — |
Q4 2018 | Oct 24, 2018 | — | $-0.16 | — | — |
Q2 2018 | Apr 3, 2018 | — | $0.15 | — | — |
Q4 2017 | Nov 2, 2017 | — | $-0.55 | — | — |
Q2 2017 | May 10, 2017 | — | $-0.56 | — | — |
Q4 2016 | Oct 24, 2016 | — | $-0.45 | — | — |
Q2 2016 | Apr 28, 2016 | — | $-0.23 | — | — |
Latest News
Frequently Asked Questions about GNRO.PA
What is GNRO.PA's current stock price?
What is the analyst price target for GNRO.PA?
What sector is GeNeuro S.A. in?
What is GNRO.PA's market cap?
Does GNRO.PA pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GNRO.PA for comparison